Genotoxicity studies with the antiestrogen toremifene

Drug and Chemical Toxicology

Volumn 21, Issue 4, 1998, Pages 449-476

  Williams, Gary M ^a   Ross, Peter M ^a   Jeffrey, Alan M ^a   Karlsson, Stefan ^b  

^a AMERICAN HEALTH FOUNDATION   (United States)

^b ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; ANTIESTROGEN; AROCLOR 1254; DNA; TAMOXIFEN; TOREMIFENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CHROMOSOME ABERRATION; CHROMOSOME DAMAGE; CONTROLLED STUDY; DNA ADDUCT; DNA SYNTHESIS; DOSE RESPONSE; DRUG STRUCTURE; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; LIVER CELL; LYMPHOCYTE; MALE; MICRONUCLEUS TEST; MOUSE; MUTAGENICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; POINT MUTATION; RAT; SALMONELLA TYPHIMURIUM;

EID: 0031729053     PISSN: 01480545     EISSN: None     Source Type: Journal    
DOI: 10.3109/01480549809002216     Document Type: Article

References (42)

1. Williams, G. M., Iatropoulos, M.J., Djordjevic, M.V., and Kaltenberg, O.P., The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat, Carcinogenesis, 14:315, 1993.
2. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, K. P., Imondi, A. R. and Williams, G. M., Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats, Cancer Resarch, 53:4534, 1993.
3. Hirsimäki, P., Hirsimäki, Y., Nieminen, L., and Payne, B.J., Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens, Archives of Toxicology, 67:49, 1993.
4. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. and Orton, T., Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats, Cancer Research, 53:3919, 1993.
5. Williams, G.M., Iatropoulos, M.J. and Karlsson, S., Initiating activity of the antiestrogen tamoxifen but not toremifene in rat liver, Carcinogenesis, 18:2247, 1997.
6. Han, X. L. and Liehr, J.G., Induction of covalent DNA adducts in rodents by tamoxifen, Cancer Research, 52:1360, 1992.
7. White, A. N. H., Matteis, F., Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer, A. and Phillips, D.H., Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells, Carcinogenesis, 13:2197, 1992.
8. Montandon, F. and Williams, G.M., Comparison of DNA reactivity of the polyphenylene hormonal agents diethylstilbestrol, tamoxifen, and toremifene in rat and hamster liver, Archives of Toxicology, 68:272, 1994.
9. Hemminki, K., Widlak, P. and Hou, S-M., DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro, Carcinogenesis, 16:1661, 1995.
10. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole K. J., Hardcastle, I. R., Poon, G. K., Keogh, A. and Strain, A. J. Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA binding products: comparison between human, rat and mouse hepatocytes, Carcinogenesis, 17:89, 1996.
11. Carmichael, P. L., Ugwumadu, A. H. N., Neven, P., Hewer, A. J., Poon, G. K. and Phillips, D. H., Lack of genotoxicity of tamoxifen in human endometrium, Cancer Research, 56:1475, 1996.
12. Hemminki, K., Rajaniemi, H. J., Koskinen, M. and Hansson, J., Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients, Carcinogenesis, 18:9, 1997.
13. IARC, Tamoxifen IARC Monographs, 66:253-366, 1996.
14. Kallio, S., Kangas, L., Blanco, G., Johansson, R., Karjalainen, A., Perilä, M., Piippo, I., Sundquist, H., Södervall, M., Toivola, R., A new triphenylethylene compound, Fc-1157a. I. Hormonal effects, Cancer Chemotherapy Pharmacology, 17:103, 1986.
15. Kangas, L. Development and biochemical pharmacology of toremifene, an antiestrogenic anticancer drug. Dissertation presented to the Department of Chemistry and Biochemistry, University of Turku, Finland. (1990).
16. Pyrhönen, S., Valavaara, R., Modig, H., Pawlicki, M., Pienkowski, T., Gundersen, S., Bauer, J., Westman, G., Lundgren, S., Blanco, G., Mella, O., Nilsson, I., Hietanen, T., Hindy, I., Vuorinen, J. and Hajba, A., Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the "nordic" phase III study, British Journal Cancer, 78:270, 1997.
17. Hayes, D. F., Van Zyl, J. A., Hacking, A., Goedhals, L., Bezwoda, W. R., Maillard, J. A. et al., Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients withy metastatic breast cancer, Journal of Clinical Oncology, 13:2556, 1995.
18. European Commission, Fareston containing Toremifene, Directorate General III, Brussels, 1996.
19. Karlsson, S., Hirsimäki, Y., Mäntylä, E., Nieminen, L., Kangas, L., Hirsimäki, P., Perry, C. J., Mulhern, M., Millar, P., Handa, J., and Williams, G. M., A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats, Drug and Chemical Toxicology, 19:245, 1996.
20. IARC, Toremifene IARC Monographs, 66, 367-388, 1996.
21. Sargent, L. M., Dragan, Y. P., Sattler, C., Bahnub, N., Sattler, G., Martin, P., Cisneros, A., Mann, J., Thorgiersson, S., Jordan, V. C., and Pitot, H. C., Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene, and idoxifene in female Sprague-Dawley rats, Carcinogenesis, 17:1051, 1996.
22. Styles, J. A., Davies, A., Lim, C. K., DeMatteis, F., Stanley, L. A., White, I. N. H., Yuan, Z-X. and Smith, L. L., Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing cytochrome P450s, Carcinogenesis, 15:5, 1994.
23. Cunningham, A., Klopman, G. and Rosenkranz, H. S., A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and their metabolites, Mutation Research, 349:85, 1996.
24. Williams, G. M., Mori, H., and McQueen, C. A., Structure-activity relationships in the rat hepatocyte DNA-repair test for 300 chemicals, Mutation Research, 221:263, 1989.
25. Heddle, J. A. and Salamone, M. F., The micronucleus assay, I In vivo In: Short-term tests for chemical carcinogens. Eds. H.F. Stich and R.H.C. San, Springer-Verlag, NY, pp. 249-251, 1979.
26. Salamone, M. F. and Mavournin, K. H., Bone Marrow Micronucleus Assay: A review of the mouse stocks used and their published mean spontaneous micronucleus frequencies, Environmental and Molecular Mutagenesis, 23:239, 1994.
27. Bishop, J., Murray, R., Webster, L., Pitt, P., Stokes, K., Fennessy, A., Oliver, I., and Leber, G., Phase I clinical and pharmacokinetic study of high-dose toremifene in postmenopausal patients with advanced breast cancer, Cancer Chemotherapy Pharmacology, 30:174, 1992.
28. Anttila, M., Valavaara, R., Kivinen, S., and Maënpää, J., Pharmacokinetics of toremifene. Journal Steroid Biochemistry, 36:249, 1990.
29. Maron, D. M. and Ames, B., Revised methods for the Salmonella mutagenicity test, Mutation Research, 113:173, 1983.
30. CFR, Code of Federal Regulations title 40 Section 798 Subpart F - genetic toxicity, 1995.
31. Davies, R., Oreffo, V. I. C., Bayliss, S., Dinh, P-A., Lilley, K. S., Whith, I. N. H, Smith, L. L., and Styles, J. A., Mutational spectra of tamoxifen-induced mutations in the livers of loci transgenic rats, Environmental and Molecular Mutagenicity, 28:430, 1996.
32. Potter, G.A., McCague, R., and Jarman, M., A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism, Carcinogenesis, 15:439, 1994.
33. Berthou, F., Dreano, Y., Belloc, C., Kangas, L., Gautier, J-C., and Baune, P., Involvement of cytochrome P450 3A enzyme family in the major metabolic pathway of toremifene in human liver microsomes, Biochemical Pharmacology, 47:1883, 1994.
34. Borlak, J. T., Scott, A., Henderson, C. J., Jenke, H. J. and Wolf, C. R., Transfer of PCBs via lactation simultaneously induces the expression of P450 isozymes and the protooncogenes c-Ha-ras and c-raf in neonates, Biochemical Pharmacology, 51:517, 1996.
35. Hemminki, K., Rajaniemi, H., Lindahl, B. and Moberger, B., Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients, Cancer Research, 56:4374, 1996.
36. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen, Carcinogenesis, 16:1651, 1995.
37. Kendall, M. E. and Rose, D. P., The effects of diethylstilbestrol, tamoxifen, and toremifene on estrogen-inducible hepatic proteins and estrogen receptor proteins in female rats, Toxicology and Applied Pharmacology, 114:127-131.
38. Dragan, V. P., Vaughan, J., Jordan, V. C. and Pitot, H. C., Comparison of the effects of tamoxifen and toremifene on liver and kidney promotion in female rats, Carcinogenesis, 16:2733, 1995.
39. Orton, T. C. and Topham, J. C., Correspondence re: "K Hemminki et al. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients," Cancer Research, 57:4148, 1997.
40. Davies, A.M., Martin, E. A., Jones, R. M., Lim, C. K., Smith, L. L. and White, I. N., Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts, Carcinogenesis, 16:539, 1995.
41. Holinka, C. F. and Gurpide, E, Peroxidase activity in glands and stroma of human endometriu, American Journal Obstetrics Gynecology, 138:599, 1980.
42. Breton-Gorius, J. and Guichard, J., Fine structural and cytochemical identification of microperoxisomes in developing human erythrocytic cells, Amercan Journal of Pathology 79:523 1975.